PLOD2 Is a Prognostic Marker in Glioblastoma That Modulates the Immune Microenvironment and Tumor Progression

por Kreße, Nina, Schröder, Hannah, Stein, Klaus-Peter, Wilkens, Ludwig, Mawrin, Christian, Sandalcioglu, Ibrahim Erol, Dumitru, Claudia Alexandra
Publicado 2022

Dynein Light Chain Protein Tctex1: A Novel Prognostic Marker and Molecular Mediator in Glioblastoma

por Dumitru, Claudia Alexandra, Brouwer, Eileen, Stelzer, Tamina, Nocerino, Salvatore, Rading, Sebastian, Wilkens, Ludwig, Sandalcioglu, Ibrahim Erol, Karsak, Meliha
Publicado 2021

Activated Tissue-Resident Mesenchymal Stromal Cells Regulate Natural Killer Cell Immune and Tissue-Regenerative Function

por Petri, Robert Michael, Hackel, Alexander, Hahnel, Katrin, Dumitru, Claudia Alexandra, Bruderek, Kirsten, Flohe, Stefanie B., Paschen, Annette, Lang, Stephan, Brandau, Sven
Publicado 2017

Progesterone Receptor Membrane Component 1 (PGRMC1) Modulates Tumour Progression, the Immune Microenvironment and the Response to Therapy in Glioblastoma

por Dumitru, Claudia Alexandra, Schröder, Hannah, Schäfer, Frederik Till Alexander, Aust, Jan Friedrich, Kreße, Nina, Siebert, Carl Ludwig Raven, Stein, Klaus-Peter, Haghikia, Aiden, Wilkens, Ludwig, Mawrin, Christian, Sandalcioglu, Ibrahim Erol
Publicado 2023